TABLE 3.

Multivariate Analyses for the Entire Cohort (n = 1000): nPSA12 as a Continuous Covariate

	RR (95% CI)	P
Biochemical failure (n = 260)*
Increasing iPSA	1.016 (1.011-1.020)	<.0001
Gleason score ≥7	1.938 (1.475-2.546)	<.0001
Increasing RT dose	0.921 (0.887-0.957)	<.0001
T3	2.122 (1.413-3.187)	.0003
Increasing nPSA12	1.018 (1.005-1.031)	.0056
Distant metastasis (n = 50)*
Gleason score ≥7	3.114 (1.718-5.646)	.0002
Increasing RT dose	0.894 (0.815-0.980)	.0169
T3	6.027 (3.115-11.662)	<.0001
Increasing nPSA12	1.037 (1.025-1.049)	<.0001
Cause-specific mortality (n = 17)*
T3	4.532 (1.451-14.156)	.0093
Increasing nPSA12	1.049 (1.033-1.065)	<.0001
Overall mortality (n = 126)*
Gleason score ≥7	1.596 (1.069-2.383)	.0223
Increasing RT dose	0.912 (0.861-0.967)	.0018
Increasing nPSA12	1.025 (1.014-1.037)	<.0001
Age	1.060 (1.031-1.091)	<.0001

RR indicates relative risk; iPSA, initial PSA; RT dose, radiotherapy dose in Gray; nPSA12, nadir PSA within 12 months of follow-up; Gleason Score.

^*Number of events for each endpoint in parentheses.